Fulcrum Therapeutics Inc (FULC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $287.96M
Last updated: Nov 17, 2026 at 11:05 AM ET
Fulcrum Therapeutics Inc (FULC) Stock Forecast
Analysts expect Fulcrum Therapeutics (FULC) to earn -$0.66 per share in the fiscal year ending Dec 31, 2026. Of 5 analysts, 0 rate the stock Buy or Strong Buy, 4 Hold and 1 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 3.40, inside the Hold band from 2.5 up to 3.5. Sell and Strong Sell make up 20% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 0 | 0.0% |
| Hold | 4 | 80.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 20.0% |
- Consensus
- Hold
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$0.66
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$0.55
- EPS consensus
- Next report
- Feb 22, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.66 | -$0.81 to -$0.51 | 3 |
| Dec 31, 2027 | -$0.55 | -$1.46 to -$0.01 | 6 |
Quarterly Estimates
The EPS consensus falls from -$0.10 for the quarter ending Dec 31, 2026 to -$0.36 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.10 | -$0.30 to -$0.02 | 8 |
| Mar 31, 2027 | -$0.36 | -$0.36 to -$0.36 | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 1 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.82.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.66 | -$0.66 | -$0.66 | -$0.76 | -$0.82 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.55 | -$0.49 | -$0.49 | -$0.58 | -$0.66 | N/A |
| Quarter ending Mar 31, 2027 | -$0.36 | -$0.30 | -$0.28 | -$0.30 | -$0.38 | N/A |
Frequently Asked Questions About FULC
What is the FULC stock forecast?
Consensus analyst estimates put Fulcrum Therapeutics's EPS at -$0.66 for the fiscal year ending Dec 31, 2026. The consensus rating from 5 analysts is Hold.
How do analysts rate FULC stock?
Of 5 analysts covering Fulcrum Therapeutics, 0 rate it Strong Buy, 0 Buy, 4 Hold, 0 Sell and 1 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from FULC next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.66, with estimates from -$0.81 to -$0.51 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.55, with estimates from -$1.46 to -$0.01 from 6 analysts.
How many analysts cover FULC?
5 analysts rate Fulcrum Therapeutics stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
FULC pages: Overview, Earnings, Forecast, Financials, Competitors